Compare GameStop Corp. (GME) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Spyre Therapeutics Inc. Common Stock — how do they compare? GameStop Corp. trades at $26.5 (market cap $13.73B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: GameStop Corp. is the larger of the two by market cap, and GameStop Corp. is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GME | SYRE | |
|---|---|---|
Market Cap | $13.73B | $7.52B |
Volume | 12,710,661 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $108.92 |
52-Week Low | $17.87 | $22.18 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $13.01B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.15, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company reported net income of $131.3M in 2025, a significant turnaround from prior losses, and holds a strong cash position of $4.77B. Recent insider buying by CEO Ryan Cohen has driven positive sentiment, with shares gaining 31% over the past month.
The outlook is mixed; strong cash reserves and insider confidence support upside, but revenue declined to $3.82B in 2025, and analyst consensus remains cautious with only 16.7% buy ratings. Key risks include execution challenges in the retail gaming sector and high valuation multiples relative to historical performance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
